百奥泰与STADA就BAT1806(托珠单抗)注射液签署授权许可与商业化协议

Core Viewpoint - The company Baiotai (688177.SH) has signed a licensing and commercialization agreement with STADA Arzneimittel AG for its BAT1806 (Tocilizumab) injection, granting STADA exclusive commercialization rights in several regions, which is expected to positively impact the company's future performance and enhance its global commercialization and profitability [1] Group 1 - The agreement involves the exclusive commercialization rights of BAT1806 (Tocilizumab) injection in the EU, Switzerland, the UK, parts of Europe, the MENA region, and certain CIS countries [1] - The total transaction amount can reach up to €136 million, including an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million, along with a double-digit percentage of net sales as revenue sharing [1] - The agreement will take effect after approval by the company's shareholders [1]